Description: Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado, with research and development operations in Waltham, Massachusetts.
Home Page: www.viridiantherapeutics.com
VRDN Technical Analysis
221 Crescent Street
Waltham,
MA
02453
United States
Phone:
617 272 4600
Officers
| Name | Title |
|---|---|
| Dr. Jonathan Violin M.B.A., Ph.D. | Co-Founder, CEO, Pres & Director |
| Mr. Kristian Humer M.B.A. | CFO, Chief Bus. Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. Barrett Katz CMO, M.B.A., M.D., MBA | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder & Member of the Scientific Advisory Board |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Mr. Vahe Bedian Ph.D. | Co-Founder & Scientific Advisor |
| Ms. Carrie Melvin M.B.A. | Chief Operating Officer |
| Dr. Rob Henderson Ph.D. | Chief Scientific Officer |
| Mr. Todd James IRC | Sr. VP of Corp. Affairs & Investor Relations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.2109 |
| Price-to-Sales TTM: | 588.21 |
| IPO Date: | 2014-06-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 50 |